Venture(US:VEMLY) Sou Hu Cai Jing·2025-08-19 02:26Group 1 - The pharmaceutical and biotechnology industry is focusing on Q2 performance and the progress of traditional Chinese medicine companies in innovative drug development, while monitoring the impact of policies such as the special governance of "Four Same Drugs" and centralized procurement of traditional Chinese medicine [1] - The valuation of some vaccine companies in the biopharmaceutical sector is at historical lows, and there is a trend of valuation recovery due to the spillover of innovative drug market sentiment [1] - The medical device sector is gradually recovering in terms of performance and valuation as the industry reaches a turning point, with recognized innovation capabilities and internationalization potential [1] Group 2 - Recent centralized procurement policies from multiple provinces or alliances have optimized rules, introducing price correction mechanisms and bottom price mechanisms, leading to some product renewal prices being increased [1] - The brain-computer interface sector is performing well, with China being relatively advanced in technology research in this field [1] - The pharmaceutical industry is showing good performance, with the release of important data and progress in research pipelines by multiple companies during the 2025 WCLC regular summary, enhancing international competitiveness and rapid development driven by new technologies and supportive national policies for innovative drug development [1] Group 3 - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which can have a daily fluctuation of up to 20%, focusing on innovative pharmaceutical fields and selecting listed company securities from biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services to reflect the overall performance of the pharmaceutical industry's innovation development [1]